Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NACT plus CCRT versus CCRT alone in locally advanced cervical cancer
ChiCTR2100054929Phase 4Recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of paclitaxel and cisplatin in Cervical Cancer (CC) (2 arms), sponsored by Sichuan Cancer Hospital. Primary endpoint: Progression-free survival. Started Mar 2022; status: recruiting.
02
Drugs
paclitaxelcisplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2100054929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054929.